Intended for healthcare professionals


NICE rejects cannabidiol for two types of treatment resistant epilepsy in children

BMJ 2019; 366 doi: (Published 23 August 2019) Cite this as: BMJ 2019;366:l5280
  1. Stijntje Dijk,
  2. Pat Lok
  1. The BMJ

The National Institute for Health and Care Excellence (NICE) has rejected cannabidiol for treating two types of severe treatment resistant epilepsy in draft guidelines.12

The independent appraisal committee highlighted its concern that the evidence showing that cannabidiol reduces the main types of seizures associated with these conditions was based on clinical trials that lasted just 14 weeks, leaving doubts about its long term effectiveness. It said that it would work with GW Pharma, which makes the cannabidiol Epidiolex, to deal with the issues raised by the committee.

Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) are types of epilepsy that begin in early childhood and are difficult to control.34 Current treatment often includes two or more antiepileptic drugs.

A 14 week double …

View Full Text

Log in

Log in through your institution


* For online subscription